PDF herunterladen
Thromb Haemost 2021; 121(12): 1622-1627
DOI: 10.1055/a-1535-9002
Cellular Haemostasis and Platelets

PF4-Dependent Immunoassays in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: Results of an Interlaboratory Comparison

Ulrich J. Sachs
1   Department of Thrombosis and Haemostasis, Giessen University Hospital, Giessen, Germany
2   Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany
,
Nina Cooper
1   Department of Thrombosis and Haemostasis, Giessen University Hospital, Giessen, Germany
2   Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany
,
Andreas Czwalinna
3   Amedes WagnerStibbe Medical Laboratory, Hannover, Germany
,
Jens Müller
4   Institute for Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany
,
Bernd Pötzsch
4   Institute for Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany
,
Andreas Tiede  ‡   *
5   Department of Haematology, Haemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
,
Karina Althaus  ‡   *
6   Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background Coronavirus disease 2019 vaccine ChAdOx1 nCov-19 may rarely lead to vaccine-induced thrombotic thrombocytopenia (VITT). Antibody-mediated, platelet factor 4 (PF4)-dependent platelet activation appears to resemble a key mechanism in VITT, partially comparable to heparin-induced thrombocytopenia. The use of PF4/heparin immunoassays has been proposed as part of a diagnostic approach, but their sensitivity has not been established.

Methods Sera from 12 well-defined VITT patients were first studied by two different laboratories in functional assays. Sera where then used for an interlaboratory comparison, in which five different PF4/heparin immunoassays were used by four laboratories.

Results Results for functional testing were highly concordant. VITT antibodies were also reliably detected by PF4/heparin enzyme-linked immunosorbent assays (ELISAs) (92–100%). In contrast, only 25% of VITT antibodies were reactive in a particle gel immunoassay (PaGIA), and 8% in a lateral flow assay (LFA). An automated chemiluminescence immunoassay (CLIA) was negative for all sera tested (0%).

Conclusion It seems feasible to establish functional antibody testing for the confirmation of VITT. For the initial screening of suspected VITT cases, PaGIA, LFA, and CLIA are useless when applied as single tests. Only ELISA-based PF4/heparin immunoassays are sensitive enough to be incorporated in the diagnostic workup. However, a combination of a positive ELISA and a negative CLIA may be useful to identify VITT antibodies in the absence of confirmatory functional assays.

Keywords

COVID-19 vaccine - thrombosis - antibody - immunoassay - platelet factor 4

Author Contributions

U.J.S., A.T., and K.A. designed the study, analyzed the data, and wrote the manuscript. N.C., A.C., J.M., B.P., and A.T. performed laboratory studies and analyzed data. All authors provided relevant material. All authors read and approved the manuscript.


* These authors contributed equally to this study.




Publikationsverlauf

Eingereicht: 15. Mai 2021

Angenommen: 22. Juni 2021

Accepted Manuscript online:
24. Juni 2021

Artikel online veröffentlicht:
19. Juli 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Kommentar zu diesem Artikel:

Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: Fraternal—Not Identical—TwinsThromb Haemost 2021; 121(12): 1558-1561
DOI: 10.1055/a-1585-6264

 

  • References

  • 1 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
    CrossrefPubMedGoogle Scholar
  • 2 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2130
    CrossrefPubMedGoogle Scholar
  • 3 Tiede A, Sachs UJ, Czwalinna A. et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccine. Blood 2021; blood.2021011958
    PubMedGoogle Scholar
  • 4 Wolf ME, Luz B, Niehaus L, Bhogal P, Bäzner H, Henkes H. Thrombocytopenia and intracranial venous sinus thrombosis after “COVID-19 vaccine AstraZeneca” exposure. J Clin Med 2021; 10 (08) 1599
    CrossrefPubMedGoogle Scholar
  • 5 Nagler M, Bachmann LM, ten Cate H, ten Cate-Hoek A. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2016; 127 (05) 546-557
    CrossrefPubMedGoogle Scholar
  • 6 Althaus K, Westphal A, Strobel U, Bakchoul T, Greinacher A. Real-life evaluation of an automated immunoassay for diagnosis of heparin-induced thrombocytopenia. Thromb Res 2020; 196: 400-403
    CrossrefPubMedGoogle Scholar
  • 7 Bankova A, Andres Y, Horn MP, Alberio L, Nagler M. Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: comparison of diagnostic accuracy, reproducibility, and costs in clinical practice. PLoS One 2017; 12 (06) e0178289
    CrossrefPubMedGoogle Scholar
  • 8 Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66 (06) 734-736
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Sachs UJ, von Hesberg J, Santoso S, Bein G, Bakchoul T. Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thromb Haemost 2011; 106 (06) 1197-1202
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 Eekels JJM, Althaus K, Bakchoul T. et al. An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2019; 17 (03) 525-531
    CrossrefPubMedGoogle Scholar
  • 11 Vianello F, Sambado L, Scarparo P. et al. Comparison of three different immunoassays in the diagnosis of heparin-induced thrombocytopenia. Clin Chem Lab Med 2015; 53 (02) 257-263
    CrossrefPubMedGoogle Scholar
  • 12 Marchetti M, Barelli S, Zermatten MG. et al. Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia. Blood 2020; 135 (14) 1171-1184
    PubMedGoogle Scholar
  • 13 Warkentin TE, Sheppard JI, Linkins L-A, Arnold DM, Nazy I. High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood 2018; 132 (12) 1345-1349
    CrossrefPubMedGoogle Scholar
  • 14 Cines DB, Yarovoi SV, Zaitsev SV. et al. Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia. Blood Adv 2016; 1 (01) 62-74
    CrossrefPubMedGoogle Scholar
  • 15 Kreimann M, Brandt S, Krauel K. et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 2014; 124 (15) 2442-2449
    CrossrefPubMedGoogle Scholar